Introduction
In 1946, the Surgeon General of the U.S. Public Health Service appointed the first of a series of advisory committees to consider the potential role of BCG vaccination in this country. After reviewing the evidence available at that time, the committee made a number of recommendations.' Among them was that the usefulness of BCG vaccination be evaluated in several different populations. The first response to this charge was a controlled trial among school children in Muscogee County, Georgia.2'3 As a contrast to that community with a tuberculosis problem that seemed about average for the United States, Puerto Rico was selected for a further large scale trial.
November 13, 1972. The tuberculosis death rate in Puerto Rico had risen througlhout the first third of the present century, reaching a peak of over 300 deaths per 100,000 in 1933. 4 Thereafter, it fell at a fairly constant rate to just below 200 per 100,000 in 1948. As in nearly all countries, the decline then accelerated rapidly for a while, so that the mortality rate in 1953 was below 50. The rate of declino then began to slow down. By 1969, the annual tuberculosis death rate had only dropped to 12 per 100,000.5
Throughout this ,entire period, mortality rates indicated that the tuberculosis problem in Puerto Rico was among the world's most serious. The situation at midcentury was clearly such that most of the world's tuberculosis experts would have unhesitatingly recommended that BCG vaccination be added to the tuberculosis control program.
Furthermore, most of them would hlave expected it to have a major impact on the problem. Tuberculosis was thought to arise mainly frorh recently infected persons, who could be protected if they were vaccinated prior to exposure. Healthy tuberculin reactors, having passed unscathed through this initial period of high risk were then believed to contribute relatively little to the tuberculosis problem.
The vaccination trials conducted by the U.S. Public
Health Service, including the, one in Puerto Rico, were designed to test both of these assumptions, specifically that most tuberculosis would arise from recently infected persons and that BCG vaccination would materially decrease their risk of developing manifest disease. The validity of these two assumptions would obviously determine the usefulness of BCG vaccination as a public health measure.
Materials and Methods
Most of the procedures of this trial have been described previously.6 The The program started in the poorer parts of the cities. Because tuberculin sensitivity was presumed to be very highin these areas, the initial screening dose of tuberculin was only 1 Tuberculin Unit (TU) of purified tuberculin. Children with less than 6 mm of induration to this screening dose were tested with 10 TU. Later in the program, the use of the 1 TU dose was discontinued, as it became apparent that there were very few severe reactions to an initial dose of 10 TU. All children with less than 6 mm of induration to 10 TU were considered eligible for vaccination. However, some of the eligible group did not wish to be vaccinated, largely because of the unfavorable publicity; they are classed as refusals. The A sizable proportion of nonreactors to 10 TU of RT reacted to the 100 TU dose. This is shown in Figure 2 diameter. An indication of the high degree of allergenicity of this vaccine is afforded by the distribution of reaction sizes among vaccinees, which is essentially the same as that observed among persons infected with Mycobacterium tuberculosis. 7 As a possible further check on the long term are shown for various demographic subgroups in 
